Olspas-P Oral Suspension is a combination analgesic and antipyretic formulation containing Mefenamic Acid (50mg/5ml) and Paracetamol (125mg/5ml). Mefenamic Acid, a nonsteroidal anti-inflammatory drug (NSAID), exerts its effect by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. Paracetamol, an analgesic and antipyretic agent, acts centrally to alleviate pain and reduce fever, though its exact mechanism remains partially understood. This synergistic combination is indicated for the relief of mild to moderate pain associated with conditions such as musculoskeletal disorders, dental pain, dysmenorrhea, and febrile states. Olspas-P Oral Suspension offers a convenient liquid formulation suitable for pediatric and adult patients who have difficulty swallowing tablets. The recommended dosage should be adhered to strictly to minimize the risk of adverse effects. Common side effects may include gastrointestinal discomfort, nausea, and allergic reactions, while prolonged use or overdose may lead to hepatotoxicity or renal impairment. Caution is advised in patients with pre-existing liver or kidney disease, peptic ulcer, or hypersensitivity to NSAIDs or paracetamol. Consultation with a healthcare professional is essential prior to use, especially in children, pregnant or lactating women, and those on concurrent medications.